RESULT 12
AAV24010
ID AAV24010 standard; DNA; 2157 BP.
XX
AC AAV24010;
XX
DT 06-AUG-1998 (first entry)
XX
DE Human FK506 binding protein, FKBP52, coding sequence.
XX
KW FK506 binding protein; FKBP52; human; immune response regulator;
KW immunosuppressant; steroid hormone receptor transformation; ds.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT CDS 100. .1479
FT /*tag= a
FT /product= "FKBP52"
XX
PN US5763590-A.
XX
PD 09-JUN-1998.
XX
PF 09-NOV-1994; 94US-00336618.
XX
PR 11-OCT-1991; 91US-00777752.
PR 16-OCT-1992; 92US-00963325.
PR 29-MAR-1994; 94US-00218989.
XX
PA (VERT-) VERTEX PHARM INC.
XX
PI Peattie DA, Livingston DJ, Harding MW;
XX
DR WPI; 1998-347419/30.
DR P-PSDB; AAW54038.
XX
PT DNA sequence encoding human FK506-binding protein - and recombinant DNA
PT molecule containing it.
XX
PS Claim 1; Fig 3; 28pp; English.
XX
CC This sequence encodes 52 kD human FK506 binding protein, referred to as
CC FKBP52, of the invention. The FKBP52 protein plays a key role in
CC regulating immune responses. FKBP52 may be useful for mediating steroid
CC hormone receptor transformation. The DNA may be used to screen for new
CC immunosuppressants, and in assays for metabolites in samples from
CC individuals taking immunosuppressants. The DNA may also be used in assays
CC for identifying natural intracellular rapamycin-like or FK506 like
CC substances, and in assays for identifying natural intracellular
CC substrates that are potential targets for other immunosuppressants
XX
SQ Sequence 2157 BP; 531 A; 551 C; 606 G; 469 T; 0 U; 0 Other;

Query Match 4.5%; Score 56.8; DB 2; Length 2157;
Best Local Similarity 47.5%; Pred. No. 1.1e-05;
Matches 280; Conservative 0; Mismatches 292; Indels 18; Gaps 3;

```
Qy   471 GGTTTAGCCATCGGTGTTGCTAGCATGAAGTCTGGTGAACGTGCGCTTGTGCATGTTGGC 530
Db   706 GGTCTGGAGAGGGCCATTCAGCGCATGGAGAAAGGAGAACATTCCATCGTGTACCTCAAG 765

Qy   531 TGGGAATTAGCTTATGGGAAAGAAGGAAACTTTTCTTTTCCCAATGTTCCACCTATGGCA 590
Db   766 CCCAGCTATGCTTTTGGCAGTGTTGGGAAGGAAAAGTT---CCAAATCCCACCAAATGCT 822

Qy   591 GACTTGTTATATGAGGTGGAAGTTATTGGGTTTGATGAAACAAAGGAGGGAAAAGCTCGC 650
Db   823 GAGCTGAAATATGAATTACACCTCAAGAGTTTTGAAAAGGCCAAGGAG---------TCT 873

Qy   651 AGTGATATGACTGTAGAGGAAAGGATTGGTGCAGCAGACAGAAGAAAAATGGATGGGAAT 710
Db   874 TGGGAGATGAATTCAGAAGAGAAGCTGGAACAGAGCACCATAGTGAAAGAGCGGGGCACT 933

Qy   711 TCTCTTTTTAAGGAGGAGAAACTGGAGGAAGCCATGCAACAGTATGAAATGGCCATAGCA 770
Db   934 GTGTACTTCAAGGAAGGTAAATACAAGCAAGCTTTACTACAGTATAAGAAGATCGTGTCT 993

Qy   771 TACATGGGGGACGATTTTATGTTTCAGCTGTATGGGAAGTACCAGGATATGGCTTTAGCA 830
Db   994 TGGCTGGAATATGAGTCTAGTTTT------TCCAATGAGGAAGCACAGAAAGCACAGGCC 1047

Qy   831 GTTAAAAACCCATGCCATCTTAACATAGCAGCTTGCCTCATCAAACTAAAACGATACGAT 890
Db  1048 CTTCGACTGGCCTCTCACCTCAACCTGGCCATGTGTCATCTGAAACTACAGGCCTTCTCT 1107

Qy   891 GAAGCAATTGGTCACTGCAACATTGTGTTGACAGAAGAAGAGAAAAACCCAAAAGCACTG 950
Db  1108 GCTGCCATTGAAAGCTGTAACAAGGCCCTAGAACTGGACAGCAACAACGAGAAGGGCCTC 1167

Qy   951 TTCAGAAGAGGGAAAGCAAAGGCAGAGCTAGGACAGATGGACTCAGCACGTGATGATTTC 1010
Db  1168 TTCCGCCGGGGAGAGGCCCACCTGGCCGTGAATGACTTTGAACTGGCACGGGCTGATTTC 1227

Qy  1011 CGAAAGGCACAAAAGTATGCTCCTGACGACAAGGCGATTAGAAGAGAGCT 1060
Db  1228 CAGAAGGTCCTGCAGCTCTACCCCAACAACAAAGCCGCCAAGACCCAGCT 1277
```

XX

PD WPI; 2002-740862/80.